External bipolar thermal annuloplasty as an adjunct to lumbar microdiscectomy for Carragee Type I and III annular defects: A matched cohort study Authors: Caner Gunerbuyuk, Idris Gurpinar, Furkan Almas, Mehmet Yigit Akgun, Utku Ozgen, Mehdi Hekimoglu, Alper Yeni, Tunc Oktenoglu, Turgut Akgul, Ozkan Ates, Ali Fahir Ozer Published: 2026 ABSTRACT IntroductionLumbar microdiscectomy is an established treatment for symptomatic lumbar disc herniation; however, persistent pain and functional limitation may occur, particularly in patients with annular defects.Research questionIs adjunctive external bipolar thermal annuloplasty (EBTA) associated with improved outcomes after lumbar microdiscectomy in patients with Carragee Type I and III annular defects?Material and methodsThis retrospective single-center matched cohort study included 60 patients with symptomatic single-level lumbar disc herniation and intraoperatively confirmed Carragee Type I or III annular defects. Thirty patients underwent microdiscectomy with adjunctive EBTA and were matched 1:1 with 30 patients treated with microdiscectomy alone based on age, sex, operated level, Carragee classification, baseline VAS-leg, VAS-back, and Oswestry Disability Index (ODI) scores. Outcomes were assessed preoperatively and at 6 and 12 months. Exploratory clinical relevance was assessed using MCID thresholds of ≥4.7 points for VAS-leg and >20 points for ODI.ResultsBoth groups improved significantly in VAS-leg, VAS-back, and ODI scores (p < 0.001). Compared with controls, the EBTA group had significantly lower VAS-leg, VAS-back, and ODI scores at both follow-ups. VAS-back decreased from 5.84 ± 1.17 to 1.20 ± 0.49 at 12 months in the EBTA group and from 5.96 ± 1.08 to 2.06 ± 0.72 in controls. EBTA was also associated with earlier return to work and higher satisfaction, without increased complications. Mean ODI improvement exceeded the MCID threshold in both groups, whereas VAS-leg exceeded the threshold at both follow-ups only in the EBTA group.Discussion and conclusionAdjunctive EBTA was associated with greater improvements in leg pain, back pain, and disability without increased perioperative morbidity. These exploratory findings require confirmation in larger prospective studies. Abbreviations (EBTA) (VAS) (ODI) (W) Introduction Lumbar disc herniation is a common cause of radicular pain and neurological deficit and remains one of the most frequent indications for spinal surgery when conservative treatment fails. Lumbar microdiscectomy continues to be the standard operative treatment, providing effective neural decompression and favorable clinical outcomes in the majority of patients. Nevertheless, a subset of patients experiences persistent postoperative pain or functional limitation despite adequate decompression, and recurrent disc herniation remains a clinically relevant concern (Groh et al., 2021). Accumulating evidence suggests that postoperative outcomes following discectomy are influenced not only by the adequacy of neural decompression but also by the morphology and competence of the annular defect. Carragee et al. demonstrated that annular defect type plays a critical role in determining clinical outcome and recurrence risk, with certain defect patterns associated with inferior results and higher rates of reherniation (Carragee et al., 2003). Disruption of annular integrity may permit continued nociceptive signaling and compromise the mechanical containment of the disc even after successful fragment removal. From a biological perspective, annular fissures are not inert structural defects. Degenerative changes within the annulus fibrosus are characterized by neovascularization, inflammatory infiltration, and ingrowth of nociceptive nerve fibers into regions that are normally sparsely innervated, transforming the annulus into an active pain generator (De Simone et al., 2024; Yeung and Tsou, 2002). This pathological transformation provides a plausible explanation for persistent discogenic or radicular pain following decompression alone and has stimulated interest in therapeutic strategies aimed at addressing annular pathology directly. Thermal annuloplasty was originally developed to treat discogenic pain by denervating nociceptive fibers and inducing collagen contraction within annular fissures through controlled radiofrequency energy delivery. Early techniques were primarily intradiscal and catheter-based, relying on indirect heating of the annulus (Tsou et al., 2004). Subsequent advances incorporated thermal annuloplasty into endoscopic discectomy procedures under direct visualization, with favorable early outcomes reported in selected patient populations, including professional athletes requiring rapid functional recovery (Sairyo et al., 2013). Building on these principles, external bipolar thermal annuloplasty (EBTA) represents an adaptation of the annuloplasty concept to standard microsurgical discectomy. By applying bipolar thermocoagulation directly to the annular tear under microscopic visualization, EBTA allows targeted treatment of disrupted annular lamellae and associated pathological tissue following fragmentectomy or limited discectomy. Compared with intradiscal techniques, this approach offers the theoretical advantages of precise energy delivery, direct visualization of tear margins, and selective denervation of nociceptive fibers while minimizing unnecessary thermal exposure. The potential utility of EBTA is likely dependent on annular defect morphology. Smaller, more contained defects, such as Carragee Type I and Type III tears, may be particularly amenable to thermal stabilization, whereas larger annular defects have been consistently associated with higher recurrence rates and inferior outcomes following discectomy (Groh et al., 2021; Anichini et al., 2015). For extensive annular disruption, alternative surgical strategies, including dynamic stabilization, have been proposed to mitigate recurrence risk (Kim et al., 2018). Despite a sound biological rationale, clinical data evaluating EBTA as an adjunct to conventional lumbar microdiscectomy remain limited, particularly in microsurgical rather than endoscopic settings. The purpose of the present study was therefore to evaluate the clinical outcomes, safety profile, and early recurrence patterns associated with the addition of EBTA to lumbar microdiscectomy in patients with Carragee Type I and Type III annular defects. Using a matched control cohort undergoing microdiscectomy alone, we aimed to determine whether targeted treatment of annular pathology confers additional clinical benefit beyond standard decompression. Materials and methods Study design and patient selection This retrospective, single-center matched cohort study included consecutive patients who underwent one-level lumbar microdiscectomy with or without external bipolar thermal annuloplasty (EBTA) between January 2023 and January 2025. The study protocol was approved by the institutional ethics committee. All procedures performed were conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants for treatment, participation and publication of anonymized clinical data. All patients presented with radicular pain, sensory deficit, and/or motor weakness attributable to lumbar disc herniation that persisted despite at least six weeks of conservative treatment. The study population was limited to patients with intraoperatively confirmed Carragee Type I or Type III annular defects, based on direct microscopic assessment of annular tear morphology. Patients with Carragee Type II or Type IV defects, recurrent lumbar disc herniation, prior surgery at the index level, spinal instability requiring fusion, spondylolisthesis greater than Grade I, infection, tumor, or inflammatory spinal disease were excluded. EBTA was introduced at our institution as an adjunctive technique during the study period. After its adoption, it was considered for consecutive eligible patients with intraoperatively confirmed Carragee Type I or Type III annular defects when the annular tear was judged suitable for direct bipolar coagulation under microscopic visualization. Treatment allocation was not randomized. The control cohort was selected from eligible patients treated with standard microdiscectomy alone before or during the early adoption phase and was subsequently matched 1:1 to the EBTA cohort. Therefore, although matching was used to reduce imbalance in selected baseline variables, residual selection bias and unmeasured confounding cannot be excluded. Two cohorts were established. The EBTA group consisted of consecutive patients treated with lumbar microdiscectomy followed by EBTA. The control group comprised patients who underwent standard lumbar microdiscectomy alone during the same period. To minimize selection bias, 1:1 matching was performed based on age, sex, operated spinal level (L3-4, L4-5, or L5-S1), Carragee classification (Type I or III), baseline Oswestry Disability Index (ODI), baseline Visual Analog Scale for leg pain (VAS-leg), and back pain (VAS-back). After matching, 30 patients were included in each cohort. Surgical procedure All procedures were performed under general anesthesia with the patient positioned prone on a radiolucent table. A standard midline posterior approach was used in all cases. Microsurgical decompression was performed under an operating microscope and consisted of limited laminotomy, flavectomy as required, gentle medial retraction of the traversing nerve root, and removal of the herniated disc fragment. The extent of fragmentectomy and discectomy was deliberately limited and guided by intraoperative assessment of annular defect morphology. In the EBTA group, external bipolar thermal annuloplasty was performed following adequate neural decompression. After exposure of the posterior annulus by careful nerve root retraction, straight and angled bipolar probes (45° and 60°) were used to coagulate the margins of the annular tear under direct microscopic visualization. Bipolar thermocoagulation was applied circumferentially along the length of the annular fissure using power settings of 15–25 W for 2–4 s per application, while maintaining a working distance of approximately 1–2 mm from adjacent neural structures. When present, lax segments of the posterior longitudinal ligament were also coagulated. The objective of EBTA was to shrink disrupted collagen fibers, stabilize the annular wall, and denervate pathological nociceptive tissue. Both EBTA and standard microdiscectomy procedures were performed by the same group of three experienced spine surgeons, who adhered to a standardized microsurgical technique across the study population. Representative intraoperative views of annular coagulation using angled bipolar probes, along with preoperative and postoperative sagittal T2-weighted magnetic resonance imaging of a sample case, are illustrated in Fig. 1.Fig. 1a,b) Coagulation of the medial annulus fibrosus and ligamentum flavum using an angled bipolar probe. c) Preoperative sagittal T2-weighted MRI image showing an extruded L4-5 disc fragment. d) Postoperative sagittal T2-weighted image demonstrating effective annular sealing after fragmentectomy. a,b) Coagulation of the medial annulus fibrosus and ligamentum flavum using an angled bipolar probe. c) Preoperative sagittal T2-weighted MRI image showing an extruded L4-5 disc fragment. d) Postoperative sagittal T2-weighted image demonstrating effective annular sealing after fragmentectomy. Clinical evaluation and follow-up Pain intensity and functional disability were assessed separately using VAS-leg and VAS-back, and functional disability was assessed using ODI (Zanoli et al., 2001). Assessments were performed preoperatively and at 6-month and 12-month postoperative follow-up visits. Neurological examinations were conducted at each visit, with specific evaluation of motor strength recovery. Return to work was recorded in weeks, and patient satisfaction was assessed using the Macnab criteria. Patients were monitored for postoperative complications, neurological deterioration, recurrent disc herniation, and reoperation for a minimum of 12 months. Recurrent disc herniation was defined as the recurrence of radicular symptoms associated with radiologically confirmed disc herniation at the index level following an initial postoperative improvement. The primary outcome measures were changes in VAS-leg pain and ODI scores at 6 and 12 months postoperatively. Secondary outcome measures included VAS-back scores, operative time, estimated blood loss, length of hospital stay, time to return to work, patient satisfaction, neurological recovery, recurrence of disc herniation, reoperation rate, and perioperative complications. Statistical analysis Statistical analyses were performed using IBM SPSS Statistics version 26.0 (IBM Corp., Armonk, NY, USA). Normality of continuous variables was assessed using the Shapiro–Wilk test. Continuous data are presented as mean ± standard deviation, and categorical variables as frequencies and percentages. Within-group comparisons across time points were analyzed using paired-samples t-tests. Between-group comparisons were conducted using independent-samples t-tests for continuous variables and chi-square or Fisher's exact tests for categorical variables, as appropriate. Ninety-five percent confidence intervals were calculated for primary outcome measures. A two-tailed p value of <0.05 was considered statistically significant. An a priori sample size analysis was performed using G-Power version 3.1. Assuming a large effect size (Cohen's d = 0.80), an alpha level of 0.05, and a power of 0.80, a minimum of 26 patients per group was required to detect a clinically meaningful difference in VAS-leg pain reduction. The final matched cohorts of 30 patients per group exceeded this requirement. An exploratory assessment of clinical relevance was performed by comparing mean changes from baseline with published MCID thresholds cited during peer review. MCID-level improvement was defined as a mean reduction of at least 4.7 points for VAS-leg and more than 20 points for ODI. VAS-back changes were presented as exploratory mean changes without MCID classification because no VAS-back-specific threshold was prespecified. Patient-level MCID responder proportions were not calculated; therefore, MCID interpretation was limited to group-level mean changes from baseline. Results A total of 60 patients were included in the final analysis, comprising 30 patients in the EBTA group and 30 matched controls who underwent microdiscectomy alone. Baseline demographic and clinical characteristics were comparable between the two cohorts, with no statistically significant differences in age, sex distribution, body mass index, smoking status, operated level, Carragee classification, baseline VAS-leg pain, or baseline ODI scores (Table 1). The majority of cases involved the L4–5 and L5–S1 levels, and Carragee Type I and Type III defects were evenly distributed between groups. All patients completed scheduled clinical follow-up at 6 and 12 months, and additional surveillance for recurrence and reoperation extended to at least 12 months postoperatively.Table 1Baseline demographic and clinical characteristics of the EBTA and control cohorts.Table 1VariableEBTA Group (n = 30)Control Group (n = 30)p valueaAge (years)44.6 ± 9.845.1 ± 10.20.82Sex (M/F)16/1417/130.79BMI (kg/m2)27.4 ± 3.127.8 ± 2.90.63Smoking (%)11 (36.7%)12 (40%)0.79Herniation Level0.94L3-43 (10%)2 (6.7%)L4-514 (46.7%)15 (50%)L5-S113 (43.3%)13 (43.3%)Carragee Type0.76Type I14 (46.7)15 (50%)Type III16 (53.3%)15 (50%)Baseline VAS-Leg7.03 ± 1.027.10 ± 1.100.74Baseline VAS-Back5.84 ± 1.175.96 ± 1.080.68Baseline ODI69.33 ± 10.1468.90 ± 9.900.87aA two-tailed p < 0.05 was considered statistically significant. Table 1Baseline demographic and clinical characteristics of the EBTA and control cohorts.Table 1VariableEBTA Group (n = 30)Control Group (n = 30)p valueaAge (years)44.6 ± 9.845.1 ± 10.20.82Sex (M/F)16/1417/130.79BMI (kg/m2)27.4 ± 3.127.8 ± 2.90.63Smoking (%)11 (36.7%)12 (40%)0.79Herniation Level0.94L3-43 (10%)2 (6.7%)L4-514 (46.7%)15 (50%)L5-S113 (43.3%)13 (43.3%)Carragee Type0.76Type I14 (46.7)15 (50%)Type III16 (53.3%)15 (50%)Baseline VAS-Leg7.03 ± 1.027.10 ± 1.100.74Baseline VAS-Back5.84 ± 1.175.96 ± 1.080.68Baseline ODI69.33 ± 10.1468.90 ± 9.900.87aA two-tailed p < 0.05 was considered statistically significant. Baseline demographic and clinical characteristics of the EBTA and control cohorts. A two-tailed p < 0.05 was considered statistically significant. Clinical outcomes Both treatment groups demonstrated significant postoperative improvements in pain and functional status compared with baseline. Patients treated with EBTA showed lower VAS-leg, VAS-back, and ODI scores at both postoperative follow-up time points compared with controls (Table 2, Fig. 2).Table 2Comparison of preoperative and postoperative VAS and ODI scores between EBTA and control cohorts.Table 2ParameterGroupPreoperative (mean ± SD)6 months (mean ± SD)12 months (mean ± SD)95% CI (Pre/6mo/12mo)Within-group p valueaBetween-group p valuebVAS-LegEBTA7.03 ± 1.022.06 ± 0.880.90 ± 0.646.65–7.41/1.72–2.40/0.66–1.14<0.0016 mo: <0.00112 mo: <0.001Control7.10 ± 1.103.10 ± 1.002.40 ± 0.906.70–7.50/2.70–3.50/2.05–2.75<0.001VAS-BackEBTA5.84 ± 1.172.70 ± 0.941.20 ± 0.495.40–6.28/2.35–3.05/1.02–1.38<0.0016 mo: <0.01912 mo: <0.001Control5.96 ± 1.083.32 ± 1.052.06 ± 0.725.56–6.36/2.93–3.71/1.79–2.33<0.001ODIEBTA69.33 ± 10.1423.80 ± 7.229.70 ± 4.3165.54–73.12/21.13–26.47/8.07–11.33<0.0016 mo: <0.00112 mo: <0.001Control68.90 ± 9.9032.50 ± 8.1021.40 ± 6.2065.10–72.70/29.40–35.60/19.10–23.70<0.001aA two-tailed p < 0.05 was considered statistically significant.bBetween-group p-values compare EBTA vs. Control at the same time point.Fig. 2Graphical representation of mean VAS and ODI scores for both groups. Table 2Comparison of preoperative and postoperative VAS and ODI scores between EBTA and control cohorts.Table 2ParameterGroupPreoperative (mean ± SD)6 months (mean ± SD)12 months (mean ± SD)95% CI (Pre/6mo/12mo)Within-group p valueaBetween-group p valuebVAS-LegEBTA7.03 ± 1.022.06 ± 0.880.90 ± 0.646.65–7.41/1.72–2.40/0.66–1.14<0.0016 mo: <0.00112 mo: <0.001Control7.10 ± 1.103.10 ± 1.002.40 ± 0.906.70–7.50/2.70–3.50/2.05–2.75<0.001VAS-BackEBTA5.84 ± 1.172.70 ± 0.941.20 ± 0.495.40–6.28/2.35–3.05/1.02–1.38<0.0016 mo: <0.01912 mo: <0.001Control5.96 ± 1.083.32 ± 1.052.06 ± 0.725.56–6.36/2.93–3.71/1.79–2.33<0.001ODIEBTA69.33 ± 10.1423.80 ± 7.229.70 ± 4.3165.54–73.12/21.13–26.47/8.07–11.33<0.0016 mo: <0.00112 mo: <0.001Control68.90 ± 9.9032.50 ± 8.1021.40 ± 6.2065.10–72.70/29.40–35.60/19.10–23.70<0.001aA two-tailed p < 0.05 was considered statistically significant.bBetween-group p-values compare EBTA vs. Control at the same time point. Comparison of preoperative and postoperative VAS and ODI scores between EBTA and control cohorts. A two-tailed p < 0.05 was considered statistically significant. Between-group p-values compare EBTA vs. Control at the same time point. Graphical representation of mean VAS and ODI scores for both groups. In the EBTA group, mean VAS-leg pain scores decreased from 7.03 ± 1.02 preoperatively to 2.06 ± 0.88 at 6 months and further to 0.90 ± 0.64 at 12 months (within-group p < 0.001). In the control group, VAS-leg scores improved from 7.10 ± 1.10 preoperatively to 3.10 ± 1.00 at 6 months and 2.40 ± 0.90 at 12 months (within-group p < 0.001). Between-group comparisons demonstrated significantly lower VAS-leg scores in the EBTA cohort at both 6 months and 12 months (both p < 0.001). VAS-back pain was also assessed as a secondary outcome. Baseline VAS-back scores were comparable between the EBTA and control groups (5.84 ± 1.17 vs. 5.96 ± 1.08, p = 0.68). In the EBTA group, mean VAS-back decreased to 2.70 ± 0.94 at 6 months and 1.20 ± 0.49 at 12 months (within-group p < 0.001). In the control group, mean VAS-back decreased to 3.32 ± 1.05 at 6 months and 2.06 ± 0.72 at 12 months (within-group p < 0.001). Between-group comparisons demonstrated significantly lower VAS-back scores in the EBTA group at both 6 months (p = 0.019) and 12 months (p < 0.001). Similarly, ODI scores in the EBTA group improved from a preoperative mean of 69.33 ± 10.14 to 23.80 ± 7.22 at 6 months and 9.70 ± 4.31 at 12 months (within-group p < 0.001). The control group showed improvement from 68.90 ± 9.90 to 32.50 ± 8.10 and 21.40 ± 6.20 at the respective follow-up intervals (within-group p < 0.001). Functional recovery, as measured by ODI, was significantly greater in the EBTA group at both postoperative time points (6 months and 12 months, both p < 0.001). Corresponding 95% confidence intervals are detailed in Table 2. Exploratory MCID-based mean-change analysis To explore the clinical relevance of the observed improvements, mean changes from baseline were compared with published MCID thresholds cited during peer review: a reduction of at least 4.7 points for VAS-leg and more than 20 points for ODI (Table 3). At 6 months, mean VAS-leg improvement was 4.97 points in the EBTA group and 4.00 points in the control group. At 12 months, mean VAS-leg improvement was 6.13 and 4.70 points, respectively. Thus, the EBTA group exceeded the VAS-leg MCID threshold at both follow-up points, whereas the control group reached this threshold at 12 months.Table 3Mean change from baseline compared with published MCID thresholds.Table 3OutcomeTime pointEBTA mean changeControl mean changep valueaVAS-Legb6 months4.974.00<0.00112 months6.134.70<0.001VAS-Backb6 months3.142.640.01912 months4.643.90<0.001ODIb6 months45.5336.40<0.00112 months59.6347.50<0.001aA two-tailed p < 0.05 was considered statistically significant.bMCID was defined as a reduction of ≥4.7 points for VAS-leg and >20 points for ODI. VAS-back changes are presented as exploratory mean changes without MCID classification. Values represent group-level mean changes from baseline, not patient-level MCID responder proportions. Table 3Mean change from baseline compared with published MCID thresholds.Table 3OutcomeTime pointEBTA mean changeControl mean changep valueaVAS-Legb6 months4.974.00<0.00112 months6.134.70<0.001VAS-Backb6 months3.142.640.01912 months4.643.90<0.001ODIb6 months45.5336.40<0.00112 months59.6347.50<0.001aA two-tailed p < 0.05 was considered statistically significant.bMCID was defined as a reduction of ≥4.7 points for VAS-leg and >20 points for ODI. VAS-back changes are presented as exploratory mean changes without MCID classification. Values represent group-level mean changes from baseline, not patient-level MCID responder proportions. Mean change from baseline compared with published MCID thresholds. A two-tailed p < 0.05 was considered statistically significant. MCID was defined as a reduction of ≥4.7 points for VAS-leg and >20 points for ODI. VAS-back changes are presented as exploratory mean changes without MCID classification. Values represent group-level mean changes from baseline, not patient-level MCID responder proportions. For ODI, both groups exceeded the 20-point MCID threshold at both follow-up points. Mean ODI improvement was 45.53 points at 6 months and 59.63 points at 12 months in the EBTA group, compared with 36.40 and 47.50 points, respectively, in the control group. VAS-back mean changes were also presented as exploratory secondary outcome changes, with improvements of 3.14 and 4.64 points in the EBTA group and 2.64 and 3.90 points in the control group at 6 and 12 months, respectively. Because individual patient-level MCID responder proportions were not calculated, this analysis should be interpreted as an exploratory group-level mean-change assessment rather than a formal responder analysis. Operative and perioperative parameters Operative characteristics are summarized in Table 4. Mean operative time was significantly longer in the EBTA group compared with the control group (53.4 ± 11.1 min vs. 44.2 ± 9.8 min; p < 0.001). Estimated blood loss, length of hospital stay, and annular defect size did not differ significantly between cohorts. No intraoperative complications related to the annuloplasty procedure were observed. All procedures were completed as planned without the need for conversion or additional intervention.Table 4Operative characteristics of the EBTA and control groups.Table 4VariableEBTA Group (n = 30)Control Group (n = 30)p valueaOperative Time (min)53.4 ± 11.144.2 ± 9.8<0.001Estimated Blood Loss (mL)42.0 ± 15.339.4 ± 14.70.47Hospital Stay (days)1.3 ± 0.51.2 ± 0.40.34Annular Defect Size (mm)4.9 ± 1.35.0 ± 1.20.78aA two-tailed p < 0.05 was considered statistically significant. Table 4Operative characteristics of the EBTA and control groups.Table 4VariableEBTA Group (n = 30)Control Group (n = 30)p valueaOperative Time (min)53.4 ± 11.144.2 ± 9.8<0.001Estimated Blood Loss (mL)42.0 ± 15.339.4 ± 14.70.47Hospital Stay (days)1.3 ± 0.51.2 ± 0.40.34Annular Defect Size (mm)4.9 ± 1.35.0 ± 1.20.78aA two-tailed p < 0.05 was considered statistically significant. Operative characteristics of the EBTA and control groups. A two-tailed p < 0.05 was considered statistically significant. Functional recovery and patient-reported outcomes Patients in the EBTA group returned to work significantly earlier than those in the control group (4.2 ± 1.5 weeks vs. 6.1 ± 2.0 weeks; p < 0.001) (Table 5). Patient satisfaction, assessed using the Macnab criteria, was higher in the EBTA cohort, with a greater proportion of patients reporting excellent outcomes (70% vs. 40%, p = 0.03). Rates of good or excellent outcomes combined were also higher in the EBTA group. Recovery of preoperative motor deficits was observed in both cohorts, with a higher proportion of leg strength recovery in the EBTA group (88% vs. 70%); however, this difference did not reach statistical significance (p = 0.09).Table 5Comparison of clinical outcomes between EBTA and control groups at follow-up.Table 5OutcomeEBTA Group (n = 30)Control Group (n = 30)p valueaReturn to Work (weeks)4.2 ± 1.56.1 ± 2.0<0.001Patient Satisfaction (Macnab)0.03Excellent21 (70%)12 (40%)Good8 (26.7%)14 (46.7%)Fair1 (3.3%)3 (10%)Poor0 (0%)1 (3.3%)Leg Strength Recovery88%70%0.09aA two-tailed p < 0.05 was considered statistically significant. Table 5Comparison of clinical outcomes between EBTA and control groups at follow-up.Table 5OutcomeEBTA Group (n = 30)Control Group (n = 30)p valueaReturn to Work (weeks)4.2 ± 1.56.1 ± 2.0<0.001Patient Satisfaction (Macnab)0.03Excellent21 (70%)12 (40%)Good8 (26.7%)14 (46.7%)Fair1 (3.3%)3 (10%)Poor0 (0%)1 (3.3%)Leg Strength Recovery88%70%0.09aA two-tailed p < 0.05 was considered statistically significant. Comparison of clinical outcomes between EBTA and control groups at follow-up. A two-tailed p < 0.05 was considered statistically significant. Recurrence, reoperation, and complications Clinical events related to recurrence, reoperation, and complications are presented in Table 6. Recurrent disc herniation within 12 months occurred in 1 patient (3.3%) in the EBTA group and 5 patients (16.7%) in the control group, representing a lower observed recurrence rate in the EBTA cohort, although this difference did not reach statistical significance (p = 0.08). Reoperation rates followed a similar pattern (3.3% vs. 13.3%, p = 0.16). Overall complication rates were low and comparable between groups. One durotomy occurred in each cohort, with no cases of permanent neurological deterioration. Wound-related complications were infrequent, and no statistically significant differences were observed between the EBTA and control groups.Table 6Recurrence, reoperation, and complication rates.Table 6VariableEBTA Group (n = 30)Control Group (n = 30)p valueaRecurrent Herniation (<12 months)1 (3.3%)5 (16.7%)0.08Reoperation Rate1 (3.3%)4 (13.3%)0.16Any Complication1 (3.3%)2 (6.7%)0.55Neurological Deterioration0 (0%)1 (3.3%)0.31Wound Problems0 (0%)1 (3.3%)0.31Durotomy1 (3.3%)1 (3.3%)1.00aA two-tailed p < 0.05 was considered statistically significant. Table 6Recurrence, reoperation, and complication rates.Table 6VariableEBTA Group (n = 30)Control Group (n = 30)p valueaRecurrent Herniation (<12 months)1 (3.3%)5 (16.7%)0.08Reoperation Rate1 (3.3%)4 (13.3%)0.16Any Complication1 (3.3%)2 (6.7%)0.55Neurological Deterioration0 (0%)1 (3.3%)0.31Wound Problems0 (0%)1 (3.3%)0.31Durotomy1 (3.3%)1 (3.3%)1.00aA two-tailed p < 0.05 was considered statistically significant. Recurrence, reoperation, and complication rates. A two-tailed p < 0.05 was considered statistically significant. Summary of findings In this matched retrospective comparison, adjunctive EBTA during lumbar microdiscectomy was associated with greater improvements in leg pain, back pain, disability, earlier return to work, and higher patient satisfaction compared with microdiscectomy alone. These findings were observed with a modest increase in operative time and without an increase in perioperative morbidity. Although lower recurrence and reoperation rates were observed in the EBTA group, these differences did not reach statistical significance and should be interpreted cautiously. Discussion Lumbar microdiscectomy remains the gold standard surgical treatment for symptomatic lumbar disc herniation, providing reliable neural decompression and substantial symptomatic improvement in the majority of patients. However, persistent postoperative pain and recurrent disc herniation continue to represent clinically relevant challenges, particularly in the presence of annular disruption and compromised annular competence. Prior work has demonstrated that surgical outcomes following discectomy are influenced not only by the adequacy of neural decompression but also by the morphology and integrity of the annular defect, with certain defect types predisposing patients to inferior outcomes and higher recurrence rates (Carragee et al., 2003). These observations have driven increasing interest in adjunctive strategies aimed at addressing annular pathology rather than decompression alone. In the present matched retrospective analysis, adjunctive external bipolar thermal annuloplasty (EBTA) during lumbar microdiscectomy was associated with significantly lower VAS-leg, VAS-back, and ODI scores at both 6 and 12 months postoperatively compared with microdiscectomy alone. Patients treated with EBTA also demonstrated earlier return to work and higher patient satisfaction. Importantly, these findings were observed without an increase in perioperative morbidity, although EBTA was associated with a modest but statistically significant increase in operative time. Nevertheless, these results should be interpreted cautiously. The study was retrospective, treatment allocation was non-randomized, and the matched sample size was small. Therefore, the observed differences should be regarded as exploratory associations rather than definitive evidence of treatment efficacy. The addition of VAS-back outcomes is particularly relevant because the proposed mechanism of EBTA involves targeted treatment of annular nociceptive tissue, which may be more directly reflected in axial or discogenic back pain than in radicular leg pain alone. In the present study, baseline VAS-back scores were comparable between groups, and both cohorts improved postoperatively. However, the EBTA cohort demonstrated significantly lower VAS-back scores at both follow-up time points. This finding supports the biological plausibility of annular intervention, while also requiring cautious interpretation because VAS-back was assessed as a secondary outcome and the study was not designed to isolate discogenic back pain as the primary indication for surgery. The biological rationale underlying annuloplasty as an adjunct to lumbar disc surgery is supported by a growing body of anatomical and pathophysiological evidence. Degenerative annular fissures are characterized by neovascularization, inflammatory infiltration, and ingrowth of nociceptive nerve fibers into regions of the annulus that are normally sparsely innervated, effectively transforming the annulus fibrosus into a potential pain generator (Groh et al., 2021; De Simone et al., 2024). This process provides a plausible explanation for persistent discogenic and radicular pain following otherwise adequate decompression and supports the concept of targeted annular intervention. Classical intradiscal thermal annuloplasty techniques were developed to address this pathology by denervating nociceptive fibers and shrinking collagen through prolonged high-temperature exposure (Tsou et al., 2004). While conceptually sound, intradiscal approaches are limited by indirect targeting, variable heat distribution, and an inability to directly visualize the annular tear or associated granulation tissue. By contrast, EBTA allows direct microscopic visualization of the disrupted annular lamellae following fragmentectomy or limited discectomy, enabling controlled coagulation of the tear margins and adjacent pathological tissue while minimizing unnecessary thermal spread. This external, targeted application of thermal energy may therefore provide more consistent denervation and mechanical stabilization of the posterior annulus. The clinical outcomes observed in the present study are consistent with this mechanistic framework. While both cohorts demonstrated significant postoperative improvement, as expected after effective microdiscectomy, patients treated with EBTA showed greater improvements in leg pain, back pain, and disability that persisted at 12 months. Exploratory MCID-based mean-change analysis also supported the clinical relevance of these improvements. Mean ODI improvement exceeded the published MCID threshold in both groups at both follow-up points, whereas mean VAS-leg improvement exceeded the MCID threshold in the EBTA group at both 6 and 12 months and reached the threshold in the control group at 12 months. VAS-back mean changes were also greater in the EBTA group, although VAS-back was not classified according to MCID because no VAS-back-specific threshold was prespecified. Importantly, because patient-level MCID responder proportions were not calculated, these findings should be interpreted as group-level exploratory evidence of clinical relevance rather than formal responder analysis. The earlier return to work and higher patient satisfaction rates observed in the EBTA group may reflect the combined effect of improved radicular pain, reduced axial pain, and better functional recovery. However, return to work is influenced by multiple non-surgical factors, including occupational demands, social circumstances, and expectations regarding recovery. Therefore, although these findings are clinically encouraging, they should be interpreted as secondary outcomes that require validation in larger prospective cohorts. From a procedural standpoint, the addition of EBTA resulted in a longer operative time, which is an expected consequence of incorporating an additional intervention under microscopic visualization. Importantly, this increase did not translate into higher blood loss, prolonged hospitalization, or increased complication rates. The overall safety profile of EBTA in this series was comparable to standard microdiscectomy, with no procedure-specific adverse events attributable to thermal application. These findings suggest that, when performed under direct visualization by experienced surgeons, EBTA can be integrated into standard microsurgical discectomy without substantially increasing perioperative risk. A lower observed rate of recurrent disc herniation and reoperation was noted in the EBTA group compared with controls; however, these differences did not reach statistical significance. Although this trend is clinically encouraging, it must be interpreted cautiously given the modest sample size and limited follow-up duration. Recurrence after lumbar discectomy is multifactorial and influenced by annular defect size, disc degeneration, biomechanical loading, and patient-specific factors (Karadağ et al., 2022). Prior studies have consistently shown that wide annular defects are associated with higher recurrence rates and inferior outcomes (Carragee et al., 2003). In this context, the selection of Carragee Type I and Type III defects in the present study is particularly relevant, as these smaller, more contained tears may be more amenable to thermal annular stabilization. For larger annular defects, alternative strategies, including annular closure devices or dynamic stabilization in selected cases, may be more appropriate and should be considered separately (Ozer et al., 2013). Several limitations of this study warrant consideration. First, the retrospective design introduces inherent risks of selection bias, despite the use of a matched control cohort. Treatment allocation was not randomized, and EBTA was introduced during the study period, which may have introduced temporal, surgeon-related, or selection-related confounding. Although matching reduced imbalance in selected baseline variables, including age, sex, operated level, Carragee classification, baseline VAS-leg, baseline VAS-back, and ODI scores, unmeasured confounders such as symptom duration, disc degeneration grade, psychosocial factors, occupational demands, and pain catastrophizing were not fully captured. Second, the small matched sample limits the stability of effect estimates and precludes definitive conclusions regarding recurrence prevention or subgroup effects. Third, although mean changes were compared with published MCID thresholds, patient-level MCID responder proportions were not calculated; therefore, the MCID analysis should be interpreted as exploratory. Fourth, functional follow-up was limited to 12 months, and routine postoperative imaging was not performed, precluding objective assessment of annular healing, fibrosis formation, or subclinical recurrence. Finally, the single-center design and involvement of experienced spine surgeons may limit generalizability to other practice settings. Despite these limitations, the present findings suggest that EBTA is a biologically plausible and technically feasible adjunct to lumbar microdiscectomy in carefully selected patients with Carragee Type I and Type III annular defects. By directly addressing annular pathology under microscopic visualization, EBTA was associated with greater improvements in leg pain, back pain, disability, and patient-reported recovery without compromising perioperative safety. However, given the retrospective design and small sample size, these findings should be considered hypothesis-generating. Prospective, randomized studies with larger cohorts, standardized assessment of leg and back pain, patient-level MCID responder analysis, postoperative imaging, and longer follow-up are required to better define the clinical value and durability of EBTA. Conclusion In this matched retrospective analysis, adjunctive external bipolar thermal annuloplasty during lumbar microdiscectomy was associated with greater improvements in leg pain, back pain, functional disability, earlier return to work, and higher patient satisfaction in patients with Carragee Type I and Type III annular defects. These findings were observed without an increase in perioperative complications, although EBTA was associated with a modest increase in operative time. Exploratory MCID-based mean-change analysis suggested that the observed improvements were clinically relevant, particularly for ODI and VAS-leg outcomes; however, patient-level MCID responder proportions were not calculated. Therefore, these findings should be interpreted as group-level exploratory evidence rather than definitive proof of clinical superiority. Although lower rates of recurrent disc herniation and reoperation were observed in the EBTA cohort, these differences did not reach statistical significance and should be interpreted cautiously. Given the retrospective design, non-randomized treatment allocation, small matched sample size, and limited follow-up, definitive conclusions regarding recurrence prevention or long-term durability cannot be drawn. In appropriately selected patients, EBTA represents a biologically plausible and technically feasible adjunct to lumbar microdiscectomy that may help address annular pathology under microscopic visualization without compromising perioperative safety. Prospective, randomized studies with larger cohorts, standardized assessment of leg and back pain, patient-level MCID responder analysis, postoperative imaging, and longer follow-up are required to clarify the clinical value and durability of this technique. Ethics approval and consent to participate All procedures performed in this study were in accordance with the ethical standards of Koc University Hospital Ethics Committee under approval code 2022.021. IRB.016. and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Consent for participation and publication Informed consent was obtained from all individual participants included in the study for their participation and their anonymized data to be published in this article. Clinical trial number Not applicable. Authors’ contributions All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by all authors. The first draft of the manuscript was written by CG, IG and MYA. All authors commented on previous versions of the manuscript. Visualization and statistical analysis were provided by FA. TO, TA, OA and AFO supervised the study. All authors read and approved the final manuscript. Availability of data and materials The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.